Latest / Stock Movers / Stock Movers: Novartis, Soitec, Nordex (Podcast)
Transcript
- 0:02Speaker 1: Bloomberg Audio Studios. Podcasts. Radio. News. The Stock Movers Report.
- 0:10Speaker 1: Your roundup of companies making moves in the stock market.
- 0:13Speaker 1: Harnessing the power of Bloomberg data.
- 0:16Speaker 2: Now, let's look at some of the stocks on the
- 0:18Speaker 2: move today here in Europe. I'm Caroline Hipkin, and we're
- 0:20Speaker 2: joined by Bloomberg reporter Chloe Millay to take us through
- 0:23Speaker 2: the names today. Let's start with Novartis. Some drug trial disappointment.
- 0:27Speaker 2: How are investors reacting? Well, quite negatively.
- 0:30Speaker 3: So, this is another setback for Novartis with a second
- 0:34Speaker 3: trial disappointment within the space of a week. So, a
- 0:37Speaker 3: few days ago, it stopped trials of an experimental cell
- 0:40Speaker 3: therapy for autoimmune diseases after three patients died. And then
- 0:45Speaker 3: late on Friday, it said that its heart drug that
- 0:48Speaker 3: had blockbuster potential actually did not translate into fewer deaths,
- 0:53Speaker 3: heart attacks and strokes compared with the placebo. So, these
- 0:57Speaker 3: are two setbacks within the space of a week, as
- 1:00Speaker 3: I mentioned. And that's, of course, quite important for Novartis,
- 1:03Speaker 3: given that a lot of its best-selling medicines are facing
- 1:07Speaker 3: generic competition. And so, it really does need to grow
- 1:10Speaker 3: that pipeline again. The CEO had said previously that some
- 1:15Speaker 3: successful late-stage trials could allow the company to raise its
- 1:19Speaker 3: forecast for sales growth through to 2030. But obviously, it
- 1:22Speaker 3: does need those trials to be successful. The next big
- 1:26Speaker 3: pipeline test is going to be an experimental injection that's
- 1:30Speaker 3: designed to tackle the genetic cause of DM1, which is
- 1:34Speaker 3: a muscle wasting disease, rather than just treating the symptoms.
- 1:38Speaker 3: And so this is going to be a very important trial.
- 1:41Speaker 3: It's also the centerpiece of its $ 12 billion acquisition of Avidity.
- 1:46Speaker 3: So that's going to be very important. The success of
- 1:48Speaker 3: that drug will be key for the outlook. And another
- 1:51Speaker 3: disappointment could, of course, weigh massively on on the shares
- 1:55Speaker 3: as it has done for those two setbacks over the
- 1:58Speaker 3: last week.
- 1:59Speaker 2: Okay. So, that's on Novartis. Next is Nordex. Who are
- 2:04Speaker 2: they and what's driving the move? Yes.
- 2:06Speaker 3: So, Nordex is a wind turbine company and it got
- 2:10Speaker 3: upgraded by Bank of America today. So, analysts said that
- 2:13Speaker 3: they see significant earnings upgrades ahead following a period of
- 2:19Speaker 3: quite significant underperformance. So, analysts have said that there was
- 2:24Speaker 3: further growth in Germany. There was also a growth in
- 2:27Speaker 3: orders from the U.S. and a stable supply chain, which
- 2:31Speaker 3: all of these are positive for the company. They also
- 2:35Speaker 3: said that the recent underperformance in the shares has been
- 2:38Speaker 3: excessive and that the prospects are not reflected.
- 2:42Speaker 2: In the valuation.
- 2:43Speaker 3: And we are seeing Nordex kind of emerging from a
- 2:47Speaker 3: difficult period for the wind industry in general. You know,
- 2:50Speaker 3: it seems that all of the big names in that
- 2:52Speaker 3: sector like Vestas and Ørsted as well are sort of
- 2:55Speaker 3: getting back on track now and benefiting from a solid
- 2:59Speaker 3: sort of order backlog and order momentum after what had
- 3:03Speaker 3: been a bit of a difficult time over 2024, 2025.
- 3:05Speaker 2: Okay. So, that from Nordex. And finally, a boost for Swatek,
- 3:11Speaker 2: which is riding the tech wave. There aren't many tech
- 3:15Speaker 2: names in Europe, but this is one.
- 3:16Speaker 1: Yeah, exactly.
- 3:17Speaker 3: So, Swatek and then other names within the semiconductor industry
- 3:22Speaker 3: are doing well today, like Nokia, Infineon, STMicro. And that
- 3:26Speaker 3: follows a pretty good session from Asian tech stocks as well.
- 3:30Speaker 3: And so, the main reason for this AI optimism today
- 3:33Speaker 3: is the launch of OpenAI's GPT-6 Astra, this new model.
- 3:38Speaker 3: And the company has positioned this new model as a
- 3:41Speaker 3: key push towards artificial general intelligence, or AGI, which refers
- 3:47Speaker 3: to software that outperforms humans at a wide range of tasks.
- 3:52Speaker 3: And AGI is considered to be a really key milestone
- 3:55Speaker 3: in AI development. But it has many different definitions. No
- 3:59Speaker 3: one can really agree on what exactly it means. But
- 4:04Speaker 3: regardless of that, we are seeing this move towards this
- 4:07Speaker 3: quite important ambition within the AI industry, sort of reviving
- 4:11Speaker 3: this AI trade today. And Swatek and those names are
- 4:14Speaker 3: that I mentioned are really benefiting from that as kind
- 4:17Speaker 3: of key suppliers of those components of data centers and
- 4:21Speaker 3: semiconductors and everything. So we're seeing the tech very much
- 4:24Speaker 3: in the green today in Europe.
- 4:26Speaker 1: The Stock Movers Report from Bloomberg Radio. Check back with
- 4:31Speaker 1: us throughout the day for the latest roundup of companies
- 4:33Speaker 1: making news on Wall Street. And for the latest market-moving headlines,
- 4:37Speaker 1: listen to Bloomberg Radio live. Catch us on YouTube, Bloomberg.com,
- 4:42Speaker 1: and on Apple CarPlay and Android Auto with the Bloomberg
- 4:45Speaker 1: Business app.